Cytophage Technologies (TSXV:CYTO.H) ROC %: -113.15% (As of Dec. 2025)


What is Cytophage Technologies ROC %?

Cytophage Technologies TSXV:CYTO.H ROC % is -113.15% as of Dec. 2025. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Cytophage Technologies's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was -113.15%.

As of today (2026-06-24), Cytophage Technologies's WACC % is 7.13%. Cytophage Technologies's ROC % is -136.03% (calculated using TTM income statement data). Cytophage Technologies earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Cytophage Technologies  (TSXV:CYTO.H) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cytophage Technologies's WACC % is 7.13%. Cytophage Technologies's ROC % is -136.03% (calculated using TTM income statement data). Cytophage Technologies earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Cytophage Technologies ROC % Related Terms

Cytophage Technologies ROC % Historical Data

* Premium members only.

The historical data trend for Cytophage Technologies's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytophage Technologies ROC % Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
-314.22 -67.90 -137.61 -118.59 -134.34

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -136.27 -142.19 -147.73 -140.72 -113.15

Cytophage Technologies ROC % Calculation

Cytophage Technologies's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-4.043 * ( 1 - 0% )/( (3.328 + 2.691)/ 2 )
=-4.043/3.0095
=-134.34 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.938 - 0.469 - ( 1.521 - max(0, 0.684 - 1.825+1.521))
=3.328

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.334 - 0.423 - ( 0.501 - max(0, 0.667 - 0.887+0.501))
=2.691

Cytophage Technologies's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-3.132 * ( 1 - 0% )/( (2.845 + 2.691)/ 2 )
=-3.132/2.768
=-113.15 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.181 - 0.632 - ( 0.341 - max(0, 0.873 - 0.577+0.341))
=2.845

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.334 - 0.423 - ( 0.501 - max(0, 0.667 - 0.887+0.501))
=2.691

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -113.15% mean?
Cytophage Technologies (TSXV:CYTO.H) has a ROC % of -113.15% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Cytophage Technologies and its competitors.
Is Cytophage Technologies' ROC % too high?
Cytophage Technologies' current ROC % is -113.15%.
How does Cytophage Technologies' ROC % compare to VRTX and REGN?
Cytophage Technologies' ROC % of -113.15% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Cytophage Technologies and its competitors. Cytophage Technologies's current ROC % is -113.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytophage Technologies stock overvalued right now?
Cytophage Technologies (TSXV:CYTO.H) has a current ROC % of -113.15%. The current ROC % is -113.15%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Cytophage Technologies (TSXV:CYTO.H), the current ROC % is -113.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cytophage Technologies Business Description

Address 400 Fort Whyte Way, Suite 200A, Oak Bluff, MB, CAN, R4G 0B1
Cytophage Technologies Ltd is a Canadian biotechnology company engaged in the development of bacteriophages using molecular genetics and synthetic biology techniques. The company focuses on developing bacteriophage-based solutions to address bacterial challenges affecting animal health, human health, and food security, including antibiotic-resistant bacterial strains.